Core Viewpoint - The company, Gaoshi Medical (02407), has announced that its subsidiary, Gaoshi Tailiang Medical Technology Co., Ltd., has officially received ISO13485:2016/EN ISO13485:2016 medical device quality management system certification from DEKRA, indicating compliance with international standards in quality management for medical devices [1] Group 1: Certification Details - The certification covers the entire process of design, development, production, and sales of intraocular lenses used for treating cataracts and presbyopia, along with their associated implantation systems [1] - DEKRA, established in 1925, is a globally recognized independent non-listed professional inspection, testing, and certification organization [1] Group 2: Importance of ISO13485 - ISO13485 is a specialized quality management system standard for the medical device industry, focusing on patient-centered risk management and comprehensive quality control throughout the product lifecycle [1] - Achieving this certification signifies that the company has established a quality management system that meets regulatory requirements and is committed to continuous improvement [1] Group 3: Strategic Implications - The acquisition of this important qualification demonstrates the company's determination to enhance its quality management system and indicates that it has reached international standards in medical device quality management, risk control, and compliance operations [1] - This certification lays a solid foundation for the company to further expand into international markets [1]

Core Viewpoint - The company has received ISO 13485:2016/EN ISO 13485:2016 certification for its medical device quality management system, indicating compliance with international standards in the medical device industry [1] Group 1: Certification Details - The certification was issued by DEKRA, a leading independent certification body established in 1925, covering a wide range of industry sectors [1] - The certification encompasses the entire process of design, development, production, and sales of intraocular lenses for cataract and presbyopia patients [1] Group 2: Importance of Certification - ISO 13485 is recognized by global medical device regulatory bodies such as China's NMPA, the EU's CE, and the US FDA, focusing on patient-centered risk management and quality control throughout the product lifecycle [1] - Achieving this certification demonstrates the company's commitment to enhancing its quality management system and signifies its capability in medical device quality management, risk control, and compliance operations at an international standard [1] Group 3: Market Implications - The acquisition of this important qualification lays a solid foundation for the company to further expand into international markets [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） ISO 13485是國際標準化組織（「ISO」）發佈的醫療器械行業專用質量管理體系標 準，聚焦「以患者為中心」的風險管理與全流程質量控制，是全球醫療器械監管 機構（如中國NMPA、歐盟CE、美國FDA等）認可的核心合規性依據。通過該認 證，意味著企業建立了覆蓋設計開發、生產、檢驗、售後等產品全生命週期的 質量管理體系，確保產品符合法規要求並持續改進。 – 1 – 本次重要資質的獲得，顯示了本公司努力提高質量管理體系的決心，且標誌著 本公司在醫療器械質量管理、風險控制及合規運營領域已達到國際標準的實力， 更為本公司進一步開拓國際市場奠定了堅實基礎。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 本公司董事（「董事」）會（「董事會」）欣然 ...

Core Insights - The company achieved a total operating revenue of 653 million yuan in H1 2025, representing a year-on-year growth of 1.72%, and a net profit attributable to shareholders of 38 million yuan, with a year-on-year increase of 33.37% [1] - The gross profit margin increased by 1.86 percentage points, indicating improved profitability [1] Revenue Breakdown - Revenue from proprietary products reached 203 million yuan, up 14.04% year-on-year, accounting for 31.09% of total revenue, an increase of 3.36 percentage points [1] - Revenue from self-produced artificial crystals contributed 171 million yuan, growing by 11.4% year-on-year, driven by national procurement policies and stable growth in overseas markets [1] - Revenue from distribution products was 327 million yuan, down 6.81% year-on-year, making up 50.09% of total revenue [1] Technical Services Performance - The technical services business showed steady growth, with revenue of 119 million yuan in H1 2025, an increase of 8.26% year-on-year, and accounting for 18.24% of total revenue, up 1.10 percentage points [1] - The company has a technical service team of 135 engineers in the Greater China region, serving nearly 14,000 clients across 13 service centers [1] R&D Investment - The company has 252 R&D personnel, representing approximately 28.0% of total employees, with R&D bases in Shenzhen, Suzhou, Wuxi, and Wenzhou domestically, and in the Netherlands and Germany internationally [2] - R&D expenditure for H1 2025 was 43.4 million yuan, a year-on-year increase of 23.6%, accounting for 21.4% of proprietary product revenue [2] Future Projections - Revenue projections for 2025-2027 are 1.564 billion, 1.715 billion, and 1.875 billion yuan, with year-on-year growth rates of 9.48%, 9.67%, and 9.33% respectively [2] - Net profit projections for the same period are 135 million, 180 million, and 214 million yuan, with year-on-year growth rates of 45.85%, 33.71%, and 18.99% respectively [2]

Gaush Meditech Ltd 高視醫療科技有限公司 (Incorporated in the Cayman Islands with limited liability) （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） (Stock Code: 2407) （股 份 代 號：2407） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders: 25 September 2025 Gaush Meditech Ltd (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.gaush.com and the websit ...

Gaush Meditech Ltd 高視醫療科技有限公司 (Incorporated in the Cayman Islands with limited liability) （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） Gaush Meditech Ltd (the "Company") — Notification of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.gaush.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the ...

(於開曼群島註冊成立的有限責任公司) 股份代號 : 2407 中期報告 2025 INTERIM REPORT 2025 (Incorporated in the Cayman Islands with limited liability) Stock Code : 2407 中期報告 2025 INTERIM REPORT | -19 | | --- | | | | | | of Children | 目錄 | 公司概況 | 2 | | --- | --- | | 公司資料 | 3 | | 財務摘要 | 5 | | 管理層討論及分析 | 6 | | 其他資料 | 18 | | 獨立審閱報告 | 23 | | 中期簡明綜合損益表 | 24 | | 中期簡明綜合全面收益表 | 25 | | 中期簡明綜合財務狀況表 | 26 | | 中期簡明綜合權益變動表 | 28 | | 中期簡明綜合現金流量表 | 29 | | 中期簡明綜合財務資料附註 | 31 | | 釋義 | 51 | 公司概況 高視醫療科技有限公司是一家於2017年11月1日根據開曼群島法律註冊成立的獲豁免有限責任公司，並於 2022年12月12日在聯 ...

Group 1 - The core viewpoint of the report is that Gaoshi Medical (02407) is expected to see revenue growth from 2025 to 2027, with projected revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, representing year-on-year growth rates of 9.48%, 9.67%, and 9.33% respectively [1] - The net profit attributable to the parent company is forecasted to be 135 million, 180 million, and 214 million yuan for the same period, with year-on-year growth rates of 45.85%, 33.71%, and 18.99% [1] - The report maintains a "buy" rating for the company, highlighting its global "4+2" research and development layout and continuous investment in R&D [1] Group 2 - In the first half of 2025, the company achieved total operating revenue of 653 million yuan, a year-on-year increase of 1.72%, and a net profit attributable to the parent company of 38 million yuan, reflecting a year-on-year growth of 33.37% [1] - The gross profit margin increased by 1.86 percentage points [1] - Revenue from self-owned products reached 203 million yuan in the first half of 2025, a year-on-year increase of 14.04%, accounting for 31.09% of total revenue, an increase of 3.36 percentage points [1] Group 3 - The revenue from self-produced artificial crystals was 171 million yuan, with a year-on-year growth of 11.4%, driven by improved customer coverage and usage due to national procurement policies [1] - Revenue from distributed products was 327 million yuan, a year-on-year decrease of 6.81%, accounting for 50.09% of total revenue [1] - The company's technical service business also showed steady growth, with revenue of 119 million yuan in the first half of 2025, an increase of 8.26%, and accounting for 18.24% of total revenue [2] Group 4 - As of the first half of 2025, the company had a technical service team of 135 engineers, serving nearly 14,000 clients across 13 service centers in Greater China [2] - The company has a total of 252 R&D and production personnel, making up approximately 28.0% of the total workforce [2] - R&D expenditures in the first half of 2025 amounted to 43.4 million yuan, a year-on-year increase of 23.6%, representing 21.4% of self-owned product revenue [2]

Group 1 - The core viewpoint of the report is that Gaoshi Medical is expected to see steady revenue growth from 2025 to 2027, with projected revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, representing year-on-year growth rates of 9.48%, 9.67%, and 9.33% respectively [1] - The net profit attributable to the parent company is forecasted to be 135 million, 180 million, and 214 million yuan for the same period, with year-on-year growth rates of 45.85%, 33.71%, and 18.99% respectively [1] - The company maintains an "overweight" rating based on its global "4+2" R&D layout and continuous investment in research and development, which has led to an expanding portfolio of proprietary products [1] Group 2 - In the first half of 2025, the company achieved total operating revenue of 653 million yuan, a year-on-year increase of 1.72%, and a net profit of 38 million yuan, up 33.37% year-on-year [1] - The gross margin increased by 1.86 percentage points, indicating improved profitability [1] - Revenue from proprietary products reached 203 million yuan, a year-on-year increase of 14.04%, accounting for 31.09% of total revenue, an increase of 3.36 percentage points [1] Group 3 - The revenue from self-produced artificial crystals contributed 171 million yuan, with a year-on-year growth of 11.4%, driven by national procurement policies enhancing customer coverage and usage, along with stable growth in overseas artificial crystal business [1] - Revenue from distributed products was 327 million yuan, a year-on-year decline of 6.81%, accounting for 50.09% of total revenue [1] Group 4 - The company's technical service business also showed steady growth, with revenue of 119 million yuan in the first half of 2025, an increase of 8.26% year-on-year, and accounting for 18.24% of total revenue, an increase of 1.10 percentage points [2] - As of the first half of 2025, the company had a technical service team of 135 engineers, serving nearly 14,000 clients across 13 service centers in Greater China [2] - The company invested significantly in R&D across various product lines, with R&D expenses of 434 million yuan in the first half of 2025, a year-on-year increase of 23.6%, representing 21.4% of proprietary product revenue [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that exceeds the market benchmark by more than 5% to 20% over the next 6-12 months [4][9]. Core Insights - The company achieved a total revenue of 653 million yuan in the first half of 2025, representing a year-on-year growth of 1.72%, while the net profit attributable to shareholders reached 38 million yuan, up 33.37% year-on-year [1][4]. - The company's self-owned product revenue increased to 203 million yuan, a growth of 14.04% year-on-year, accounting for 31.09% of total revenue, with significant contributions from self-produced artificial crystals [1][2]. - The company has a robust R&D investment strategy, with R&D expenses amounting to 434 million yuan in the first half of 2025, a 23.6% increase year-on-year, representing 21.4% of self-owned product revenue [2][4]. Financial Performance Summary - For the fiscal years 2025 to 2027, the company is projected to achieve revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, with respective growth rates of 9.48%, 9.67%, and 9.33% [2][8]. - The net profit attributable to shareholders is expected to grow to 135 million, 180 million, and 214 million yuan over the same period, with growth rates of 45.85%, 33.71%, and 18.99% respectively [2][8]. - The earnings per share (EPS) are projected to be 0.91, 1.22, and 1.45 yuan for 2025, 2026, and 2027, respectively [2][8].